LLY Latest Press Releases

-- December 12, 2025 --

Updated data for Lilly's Inluriyo (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio (abemaciclib) in ER+, HER2- advanced breast cancer PRNewswire 11:45 AM

-- December 11, 2025 --

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial PRNewswire 6:45 AM

-- December 9, 2025 --

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama PRNewswire 3:30 PM

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition PRNewswire 8:29 AM

Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-nave CLL/SLL PRNewswire 7:30 AM

-- December 8, 2025 --

Lilly declares first-quarter 2026 dividend PRNewswire 2:06 PM

Carolyn Bertozzi returns to Lilly board of directors PRNewswire 10:00 AM

-- December 7, 2025 --

Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib) PRNewswire 4:30 PM

-- December 3, 2025 --

U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor PRNewswire 1:00 PM

-- November 24, 2025 --

Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium PRNewswire 4:30 PM

Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting PRNewswire 12:00 PM

Biotech Valuations Rise as New Clinical Platforms Show Progress Globe Newswire 8:30 AM

-- November 19, 2025 --

Lilly announces plans to open Lilly Gateway Labs site in Philadelphia PRNewswire 6:45 AM

-- November 18, 2025 --

Lilly to participate in Citi's 2025 Global Healthcare Conference PRNewswire 10:00 AM

-- November 17, 2025 --

Vida Ventures Marks Fourth Major Portfolio Acquisition in 2025, Capping a Record-Setting Year for Its Science-Led, Discipline-Driven Strategy Business Wire 6:07 PM

-- November 10, 2025 --

Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection' PRNewswire 9:13 AM

-- November 6, 2025 --

Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth PRNewswire 4:06 PM

Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans PRNewswire 1:54 PM

Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight PRNewswire 6:45 AM

-- November 3, 2025 --

Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide PRNewswire 8:30 AM

-- October 30, 2025 --

Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance PRNewswire 6:45 AM

-- October 29, 2025 --

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States PRNewswire 10:30 AM

LillyDirect and Walmart Pharmacy launch first retail pick-up option with direct-to-consumer pricing for Zepbound PRNewswire 7:00 AM

-- October 28, 2025 --

Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients PRNewswire 2:30 PM

Lilly announces roster of Team USA athletes for the Olympic and Paralympic Games Milano Cortina 2026, pledges to translate U.S. Olympic and Paralympic milestones into meaningful community impact PRNewswire 10:00 AM

-- October 27, 2025 --

Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis PRNewswire 4:05 PM

Lilly declares fourth-quarter 2025 dividend PRNewswire 2:00 PM

Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea PRNewswire 1:00 PM

Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis PRNewswire 6:45 AM

-- October 25, 2025 --

Adverum Biotechnologies Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Adverum Biotechnologies, Inc. - ADVM Business Wire 11:41 AM

-- October 24, 2025 --

Lilly to Acquire Adverum Biotechnologies PRNewswire 8:30 AM

Lilly's EBGLYSS (lebrikizumab-lbkz) delivered durable disease control when administered once every eight weeks in patients with moderate-to-severe atopic dermatitis PRNewswire 6:45 AM

Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial PRNewswire 6:45 AM

-- October 21, 2025 --

Big Pharma Just Put Peptides Back on the Map - Which Players Are Still Under the Radar? AB Digital Inc 3:34 PM

-- October 17, 2025 --

Lilly's Verzenio (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment PRNewswire 8:00 AM

-- October 16, 2025 --

Lilly confirms date and conference call for third-quarter 2025 financial results announcement PRNewswire 10:01 AM

-- October 15, 2025 --

Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes PRNewswire 6:45 AM

-- October 13, 2025 --

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting PRNewswire 6:45 AM

-- October 7, 2025 --

Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis PRNewswire 6:45 AM

-- September 26, 2025 --

Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem PRNewswire 8:30 AM

-- September 25, 2025 --

Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease PRNewswire 6:39 PM

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer PRNewswire 2:01 PM

-- September 23, 2025 --

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas PRNewswire 1:00 PM

-- September 17, 2025 --

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes PRNewswire 6:01 PM

Lilly's oral GLP-1, orforglipron, superior to oral semaglutide in head-to-head trial PRNewswire 9:01 AM

-- September 16, 2025 --

Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine PRNewswire 6:01 PM

Lilly announces plans to build $5 billion manufacturing facility in Virginia PRNewswire 10:30 AM

-- September 11, 2025 --

Lilly to participate in Bernstein's 2nd Annual Healthcare Forum PRNewswire 10:00 AM

-- September 9, 2025 --

Lilly launches new "Brain Health Matters" campaign in partnership with Julianne Moore, empowering the public to prioritize brain health PRNewswire 8:00 AM

Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment PRNewswire 7:00 AM

-- September 8, 2025 --

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with treatment-nave CLL/SLL PRNewswire 6:45 AM

-- September 4, 2025 --

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain newly diagnosed metastatic KRAS G12C-mutant lung cancers PRNewswire 6:45 AM

-- September 3, 2025 --

Defiance Launches LLYZ: The First 2X Short ETF for Eli Lilly Globe Newswire 9:30 AM

-- September 1, 2025 --

Eli Lilly (LLY) Rival Novo Nordisk's Stock Pops in Europe on Wegovy Data TipRanks 11:09 AM

-- August 30, 2025 --

??? ?? ? ???: ??? ??, ??????, ?? ? ??? ?? ??? ?? ?? Benzinga Senior Editor 9:49 PM

??? ??? ?: ?? ??, ??????, ?? - ??? ??? ?? ??? ?? ?? ??? ??? Benzinga Senior Editor 8:01 AM

Toros y osos de Benzinga: Eli Lilly, Firefly, Marvell - Y las insinuaciones de inversin de Trump impulsan las acciones de defensa Benzinga Senior Editor 8:00 AM

??????????????:??????????????????-?????????????????????? Benzinga Senior Editor 8:00 AM

Bull e Orsi di Benzinga: Eli Lilly, Firefly, Marvell - E Suggerimenti sugli Investimenti di Trump Stimolano le Azioni della Difesa Benzinga Senior Editor 8:00 AM

Benzinga Bullen und Bren: Eli Lilly, Firefly, Marvell - und Trump-Investmenthinweise steigern Verteidigungsaktien Benzinga Senior Editor 8:00 AM

Benzinga?????:Eli Lilly?Firefly?Marvell--??????????????? Benzinga Senior Editor 8:00 AM

Bulls and Bears de Benzinga : Eli Lilly, Firefly, Marvell - Et les indications d'investissement de Trump stimulent les actions de dfense Benzinga Senior Editor 8:00 AM

???? ????????? ??????? ???????: ??? ????? ????????? ????? - ???????? ????????? ?? ????? ???? ???? ?????? Benzinga Senior Editor 8:00 AM

Benzinga Bulls And Bears: Eli Lilly, Firefly, Marvell - And Trump Investment Hints Boost Defense Stocks Benzinga Senior Editor 8:00 AM

Oklo, KDP, CoreWeave, Eli Lilly, Canada Goose: Trending by Analysts TipRanks 5:06 AM

-- August 27, 2025 --

Lilly's Verzenio (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy PRNewswire 6:45 AM

-- August 26, 2025 --

Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity PRNewswire 6:45 AM

-- August 25, 2025 --

Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference PRNewswire 9:00 AM

Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib Globe Newswire 8:00 AM

-- August 22, 2025 --

Lilly to participate in Wells Fargo 20th Annual Healthcare Conference PRNewswire 9:00 AM

-- August 21, 2025 --

Eli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm Globe Newswire 5:25 PM

-- August 20, 2025 --

Anne White to Retire as Executive Vice President and President, Lilly Neuroscience PRNewswire 9:00 AM

-- August 7, 2025 --

Lilly reports second-quarter 2025 financial results and raises guidance PRNewswire 6:45 AM

Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity PRNewswire 6:25 AM

-- July 31, 2025 --

Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease PRNewswire 6:45 AM

-- July 30, 2025 --

Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease PRNewswire 8:01 AM

-- July 29, 2025 --

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL PRNewswire 6:45 AM

-- July 25, 2025 --

Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk PRNewswire 8:49 AM

Donanemab receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP) in early symptomatic Alzheimer's disease PRNewswire 6:27 AM

-- July 24, 2025 --

Lilly confirms date and conference call for second-quarter 2025 financial results announcement PRNewswire 10:00 AM

Lilly and Verve announce expiration of Verve tender offer PRNewswire 8:00 AM